kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Biotinylated Human CD19, Fc Tag, ultra sensitivity (primary amine labeling), 25µg  

Recombinant Biotinylated Human CD19, Fc Tag, ultra sensitivity (primary amine labeling), 25µg

Recombinant Biotinylated Human CD19, expressed from human HEK293 cells, Fc Tag, ultra sensitivity (primary amine labeling) DMF Filed

recombinant, human, biotinylated, protein, CD19,B4,CVID3,MGC12802

More details


Availability: within 7 days

462,00 €

B-lymphocyte antigen CD19, is a single-pass type I membrane protein which contains two Ig-like C2-type (immunoglobulin-like) domains. CD19 is expressed on follicular dendritic cells and B cells. Upon activation, the cytoplasmic tail of CD19 becomes phosphorylated, which leads to binding by Src-family kinases and recruitment of PI-3 kinase. As on T cells, several surface molecules form the antigen receptor and form a complex on B lymphocytes. The (almost) B cell-specific CD19 phosphoglycoprotein is one of these molecules. The others are CD21 and CD81. These surface immunoglobulin (sIg)-associated molecules facilitate signal transduction. On living B cells, anti-immunoglobulin antibody mimicking exogenous antigen causes CD19 to bind to sIg and internalize with it. The reverse process has not been demonstrated, suggesting that formation of this receptor complex is antigen-induced. This molecular association has been confirmed by chemical studies. Mutations in CD19 are associated with severe immunodeficiency syndromes characterized by diminished antibody production. CD19 has been shown to interact with: CD81, CD82, Complement receptor 2, and VAV2.

MABSol® Recombinant Biotinylated Human CD19, Fc Tag, primary amine labeling (CD9-H8259) is expressed from human HEK293 cells. It contains AA Pro 20 - Lys 291 (Accession # P15391-1). It is the biotinylated form of Human CD19, Fc Tag (Cat. No. CD9-H5259).
Predicted N-terminus: Pro 20

Molecular Characterization
This protein carries a human IgG1 Fc fragment at the C-terminus. The protein has a calculated MW of 56.3 kDa. The protein migrates as 60-90 kDa on a SDS-PAGE gel under reducing (R) condition due to glycosylation.

The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with biotins using standard chemical labeling method. A standard biotin reagent (13.5 angstroms) is used in this product.

Less than 1.0 EU per μg by the LAL method.

>95% as determined by reduced SDS-PAGE.

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Please refer to product data sheet.

Clinical and Translational Updates

(1) "Role of chimeric antigen receptor T-cell therapy: bridge to transplantation or stand-alone therapy in pediatric acute lymphoblastic leukemia"
Qayed, Bleakley, Shah
Curr Opin Hematol (2021)
(2) "Loncastuximab tesirine for treatment of relapsed or refractory diffuse large B cell lymphoma"
Goparaju, Caimi
Expert Opin Biol Ther (2021)
(3) "Clinical and Product Features Associated with Outcome of DLBCL Patients to CD19-Targeted CAR T-Cell Therapy"
Lamure, Van Laethem, De Verbizier et al
Cancers (Basel) (2021) 13 (17)
Showing 1-3 of 13096 papers.
Please refer to product data sheet.